Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: invest04 who wrote (680)	12/23/1997 5:58:00 PM
From: JanyBlueEyes	Respond to of 5736

3 For 2 Forward Stock Split News NEW YORK--(BUSINESS WIRE)--Dec. 23, 1997--Chromatics Color Sciences International Inc. (NASDAQ:CCSI) announced today that the board of directors of the company has adopted proposals for submission to the shareholders for their approval in order to effect (i) a 3 for 2 forward split of the outstanding shares of common stock, (ii) an extension to Dec. 31, 2000 of the expiration date of the conversion feature of the company's Series A preferred stock and (iii) a revision to the market price conversion feature of the Series A preferred stock to adjust for the stock split and a revision to modify certain performance goals. These matters will be presented to the shareholders in the near future for their review and approval. The board of directors has also added a new independent director to the company's board of directors, Edmund Vimond. Vimond is a former CEO of Shulton (a subsidiary of American Cyanamid Co.) and R.J. Reynolds Tobacco International, in addition to holding earlier management positions at Johnson and Johnson and Warner-Lambert Co. "We are very pleased that Mr. Vimond is joining us during this next phase in the company's development," said Darby S. Macfarlane, chief executive officer, CCSI. The company is engaged in the business of color science and has developed technologies with medical applications involving the detection and monitoring of certain chromogenic diseases. These technologies also have other applications including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty aid and fashion industries. The company's common stock is traded on NASDAQ under the symbol "CCSI." Certain of the matters discussed in this announcement contain forward-looking statements ...........

To: invest04 who wrote (680)	12/23/1997 6:05:00 PM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 5736

News - 2 New Members Of Medical Advisory Board NEW YORK--(BUSINESS WIRE)--Dec. 23, 1997--Chromatics Color Sciences International Inc. (NASDAQ:CCSI) is pleased to announce that two new members have joined the company's medical advisory board signing exclusive agreements with the company in the field of noninvasive Bilirubinometry. The first new member, Dr. Ian Holzman, chief, division of newborn medicine at Mt. Sinai Hospital in New York City was also the principal investigator for the company's extensive clinical trials conducted at Mt. Sinai Hospital for the company's 510k submission on noninvasive monitoring of bilirubin jaundice. The second new member, Dr. M. Jeffrey Maisels, chairman, dept. of pediatrics, William Beaumont Hospital, clinical professor of pediatrics, University of Michigan Medical School, is an internationally recognized medical expert in Bilirubin infant jaundice. Dr. Maisels has written extensively on bilirubin. "We are fortunate indeed to have Dr. Maisels and Dr. Holzman's expert assistance in moving forward into global presentation to the medical community of our medical systems for noninvasive monitoring of Bilirubin...", said Darby Macfarlane, CEO of CCSI. In other related news, the company announced today that of the warrants outstanding since the company received FDA clearance on July 30, 1997, 1,138,992 warrants have been exercised for $5 per share generating $5,694,960 in proceeds, and bringing the company's cash balance to $9,385,000 at Nov. 15, 1997. The company is engaged in the business of color science.................. Certain of the matters discussed in this announcement contain forward-looking statements ...............